These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 33377969)

  • 1. Selective Use of Radioactive Iodine Therapy for Papillary Thyroid Cancers With Low or Lower-Intermediate Recurrence Risk.
    Grani G; Lamartina L; Alfò M; Ramundo V; Falcone R; Giacomelli L; Biffoni M; Filetti S; Durante C
    J Clin Endocrinol Metab; 2021 Mar; 106(4):e1717-e1727. PubMed ID: 33377969
    [TBL] [Abstract][Full Text] [Related]  

  • 2. UNFAVORABLE RESPONSES TO RADIOIODINE THERAPY IN N1B PAPILLARY THYROID CANCER: A PROPENSITY SCORE MATCHING STUDY.
    Liu YQ; Li H; Liu JR; Lin YS
    Endocr Pract; 2019 Dec; 25(12):1286-1294. PubMed ID: 31412228
    [No Abstract]   [Full Text] [Related]  

  • 3. Is surgical resection without radioactive iodine treatment a safe alternative treatment for T1-2N1bM0 papillary thyroid carcinoma?
    Fujiwara T; Yoshizawa A; Mizuta M; Tamaki H
    Auris Nasus Larynx; 2021 Feb; 48(1):148-153. PubMed ID: 32718811
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical response to radioactive iodine therapy for prophylactic central neck dissection is not superior to total thyroidectomy alone in cN0 patients with papillary thyroid cancer.
    Lin B; Qiang W; Wenqi Z; Tianyu Y; Lina Z; Bin J
    Nucl Med Commun; 2017 Dec; 38(12):1036-1040. PubMed ID: 28953211
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-Dose RAI Therapy Justified by Pathological N1a Disease Revealed by Prophylactic Central Neck Dissection for cN0 Papillary Thyroid Cancer Patients: Is it Superior to Low-Dose RAI Therapy?
    Wei L; Bai L; Zhao L; Yu T; Ma Q; Ji B
    World J Surg; 2019 May; 43(5):1256-1263. PubMed ID: 30684002
    [TBL] [Abstract][Full Text] [Related]  

  • 6. RAI therapy in low-risk papillary thyroid cancer: recurrence reduction and long-term outcomes in the Turkish population.
    Bilgic S; Meral R; Sağer MS; Sönmezoğlu K
    BMC Cancer; 2024 Oct; 24(1):1273. PubMed ID: 39402494
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcome of patients with papillary thyroid carcinoma who have recurrence after initial radioactive iodine therapy.
    Vassilopoulou-Sellin R; Schultz PN; Haynie TP
    Cancer; 1996 Aug; 78(3):493-501. PubMed ID: 8697396
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association of Radioactive Iodine Administration After Reoperation With Outcomes Among Patients With Recurrent or Persistent Papillary Thyroid Cancer.
    Hung ML; Wu JX; Li N; Livhits MJ; Yeh MW
    JAMA Surg; 2018 Dec; 153(12):1098-1104. PubMed ID: 30140908
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma.
    Kim HJ; Kim NK; Choi JH; Kim SW; Jin SM; Suh S; Bae JC; Min YK; Chung JH; Kim SW
    Clin Endocrinol (Oxf); 2013 Apr; 78(4):614-20. PubMed ID: 22957654
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microscopic positive margins in papillary thyroid cancer do not impact disease recurrence.
    Abraham E; Tran B; Roshan D; Graham S; Lehane C; Wykes J; Campbell P; Ebrahimi A
    ANZ J Surg; 2018 Nov; 88(11):1193-1197. PubMed ID: 29701284
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Noninferior response in BRAF(V600E) mutant nonmetastatic papillary thyroid carcinoma to radioiodine therapy.
    Li J; Liang J; Zhao T; Lin Y
    Eur J Nucl Med Mol Imaging; 2016 Jun; 43(6):1034-9. PubMed ID: 26780618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of delayed initial radioactive iodine therapy and clinical outcomes in papillary thyroid cancer: a two-center retrospective study.
    He T; Li M; Gao ZL; Li XY; Zhong HR; Ding CS; Cai HW
    Nucl Med Commun; 2024 Sep; 45(9):779-787. PubMed ID: 38832411
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oncocytic Papillary Thyroid Carcinoma and Oncocytic Poorly Differentiated Thyroid Carcinoma: Clinical Features, Uptake, and Response to Radioactive Iodine Therapy, and Outcome.
    Lukovic J; Petrovic I; Liu Z; Armstrong SM; Brierley JD; Tsang R; Pasternak JD; Gomez-Hernandez K; Liu A; Asa SL; Mete O
    Front Endocrinol (Lausanne); 2021; 12():795184. PubMed ID: 34975765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term clinical outcomes and prognostic factors for patients with papillary thyroid carcinoma with other organ invasions after adjuvant radioactive iodine.
    Kawamoto T; Shikama N; Fukumori T; Hoshi M; Yamada T
    Endocrine; 2023 Apr; 80(1):79-85. PubMed ID: 36367673
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Radioactive iodine (RAI) therapy for distantly metastatic differentiated thyroid cancer (DTC) in juvenile versus adult patients.
    Kammori M; Fukumori T; Sugishita Y; Hoshi M; Shimizu K; Yamada T
    Endocr J; 2015; 62(12):1067-75. PubMed ID: 26424174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Radioactive iodine ablation may not decrease the risk of recurrence in intermediate-risk papillary thyroid carcinoma.
    Kim SK; Woo JW; Lee JH; Park I; Choe JH; Kim JH; Kim JS
    Endocr Relat Cancer; 2016 May; 23(5):367-76. PubMed ID: 26917553
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intermediate-Risk Papillary Thyroid Cancer: Risk Factors for Early Recurrence in Patients with Excellent Response to Initial Therapy.
    Llamas-Olier AE; Cuéllar DI; Buitrago G
    Thyroid; 2018 Oct; 28(10):1311-1317. PubMed ID: 30105948
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Radioactive iodine therapy strategies for distinct types of differentiated thyroid cancer: a propensity score-matched analysis.
    Guo H; Zhang N; Hu Y; Zhang F; Huang T; Shen N
    Front Endocrinol (Lausanne); 2023; 14():1158581. PubMed ID: 37664843
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Post-operative stimulated thyroglobulin and neck ultrasound as personalized criteria for risk stratification and radioactive iodine selection in low- and intermediate-risk papillary thyroid cancer.
    Orlov S; Salari F; Kashat L; Freeman JL; Vescan A; Witterick IJ; Walfish PG
    Endocrine; 2015 Sep; 50(1):130-7. PubMed ID: 25792004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Undetectable thyroglobulin after total thyroidectomy in patients with low- and intermediate-risk papillary thyroid cancer--is there a need for radioactive iodine therapy?
    Ibrahimpasic T; Nixon IJ; Palmer FL; Whitcher MM; Tuttle RM; Shaha A; Patel SG; Shah JP; Ganly I
    Surgery; 2012 Dec; 152(6):1096-105. PubMed ID: 23158181
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.